ArticleACS chemical biology2022

Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis.

Scott Scarneo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.